Incidence Of Transfusion-related Acute Lung Injury Research Articles

The incidence of transfusion-related acute lung injury using active surveillance: A systematic review and meta-analysis.

Transfusion-related acute lung injury (TRALI) is a leading cause of transfusion-related mortality. A concern with passive surveillance to detect transfusion reactions is underreporting. Our aim was to obtain evidence-based estimates of TRALI incidence using meta-analysis of active surveillance studies and to compare these estimates with passive surveillance. We performed a systematic review and meta-analysis of studies reporting TRALI rates. A search of Medline and Embase by a research librarian identified studies published between January 1, 1991 and January 20, 2023. Prospective and retrospective observational studies reporting TRALI by blood component (red blood cells [RBCs], platelets, or plasma) were identified and all inpatient and outpatient settings were eligible. Adult and pediatric, as well as general and specific clinical populations, were included. Platelets and plasma must have used at least one modern TRALI donor risk mitigation strategy. A random effects model estimated TRALI incidence by blood component for active and passive surveillance studies and heterogeneity was examined using meta-regression. Eighty studies were included with approximately 176-million blood components transfused. RBCs had the highest number of studies (n = 66) included, followed by platelets (n = 35) and plasma (n = 34). Pooled TRALI estimates for active surveillance studies were 0.17/10,000 (95% confidence intervals [CI]: 0.03-0.43; I2 = 79%) for RBCs, 0.31/10,000 (95% CI: 0.22-0.42; I2 = <1%) for platelets, and 3.19/10,000 (95% CI: 0.09-10.66; I2 = 86%) for plasma. Studies using passive surveillance ranged from 0.02 to 0.10/10,000 among the various blood components. In summary, these estimates may improve a quantitative understanding of TRALI risk, which is important for clinical decision-making weighing the risks and benefits of transfusion.

Transfusion-Related Acute Lung Injury (TRALI): A Narrative Literature Review

Transfusion-related acute lung injury (TRALI) is defined as the onset of respiratory distress in a patient after receiving a blood component transfusion. So far, TRALI is considered a rare complication in the field of blood transfusion. However, in the last decade, there has been a shift in perspective. Currently, the US Food and Drug Administration recognizes the syndrome as the leading cause of transfusion-related death. This literature review aims to describe TRALI and its prevention strategies. Understanding the pathogenesis of TRALI drives prevention strategies from a blood bank perspective. A major breakthrough in efforts to reduce the incidence of TRALI was excluding female donors from the high plasma volume product, which resulted in an approximately two-thirds reduction in incidence. However, this strategy has not completely eliminated complications of transfusion. In recent years, research has identified patient-associated risk factors for the development of TRALI and empowered clinicians to take an individualized approach to patients requiring transfusion.

The epidemiology of transfusion-related acute lung injury: A scoping review and analysis.

The purpose of this scoping review was to identify available sources of evidence on the epidemiology of transfusion-related acute lung injury (TRALI) and whether meta-analysis on the incidence of TRALI is feasible. TRALI is a serious complication and the second leading cause of death related to blood transfusion. Estimates of the incidence of TRALI would provide a useful benchmark for research to reduce TRALI. We searched the Medline, EMBASE, and PubMed databases for publications related to the incidence of TRALI and hemovigilance. We included all studies irrespective of language or country. Both full-text articles and conference abstracts were included. Participants of the studies must all have received a blood transfusion. Reviews and case studies were excluded. We identified 427 articles or abstracts to include for review. More than half were abstracts, and the majority were published after 2010. Reported TRALI definitions varied, but only 27.2% of studies reported any definition for TRALI. TRALI rates were reported using different denominators, such as per blood unit (54.1%), patient (34.4%), and transfusion episode (14.8%). Study populations and contexts were mostly general (75.6% and 80.3%, respectively). There was also variation in study design with most being observational (90.6%) and only 13.1% of all studies used modern donor restriction policies. There was substantial variation in reporting in studies on TRALI incidence. Meta-analysis of TRALI rates may be feasible in specific circumstances where reporting is clear. Future studies should clearly report key items, such as a TRALI definition.

Transfusion-related acute lung injury (TRALI): a retrospective review of reported cases in Queensland, Australia over 20 years.

Transfusion-related acute lung injury (TRALI) is a rare but potentially fatal transfusion reaction. An effective haemovigilance programme is important in implementing successful and targeted risk reduction strategies. We aim to provide a summary of TRALI cases referred for investigation in Queensland (QLD) Australia from 1999 to 2019, describing the epidemiological and laboratory features of local TRALI cases. A retrospective audit evaluated all cases reported to the QLD Australian Red Cross Lifeblood over the 20-year study period. Cases were categorised according to the 2004 Canadian consensus criteria. Of the 91 cases referred for investigation, expert review confirmed 30 of TRALI and 18 of possible TRALI. A total of 238 donors and 110 blood products were assessed in confirmed cases. TRALI affected patients of all ages. Most patients had underlying haematological malignancies (25%), surgery (15%) or liver disease (13%). TRALI incidence was measured at 1 in 130,000 per issued product in QLD. Red cells were transfused in 32 cases, platelets in 18 and plasma products in 21, with 16 cases involving multiple products. Following laboratory assessment, 23% of cases had findings supportive of antibody mediated TRALI and 21% as likely non-antibody mediated. Possible TRALI was identified in 37.5% of cases of which 25% were antibody mediated and 12.5% non-antibody mediated. Nine (18.5%) cases were uncategorised due to insufficient immunologic investigations. Rates of TRALI incidence measured are lower than those seen in many international studies. A reduction in confirmed cases has been noted over recent years, supporting the implementation of risk-reduction strategies. We report a relatively higher proportion of non-antibody mediated TRALI and possible TRALI cases in more recent years, suggesting the need to further understand the role of product age and biological risk modifiers.

Incidence of transfusion-related acute lung injury temporally associated with solvent/detergent plasma use in the ICU: A retrospective before and after implementation study.

BackgroundTransfusion‐related acute lung injury (TRALI) is a severe complication of plasma transfusion, though the use of solvent/detergent pooled plasma (SDP) has nearly eliminated reported TRALI cases. The goal of this study was to investigate the incidence of TRALI in intensive care units (ICU) following the replacement of quarantined fresh frozen plasma (qFFP) by SDP.Study design and methodsA retrospective multicenter observational before–after cohort study was performed during two 6‐month periods, before (April–October 2014) and after the introduction of SDP (April–October 2015), accounting for a washout period. A full chart review was performed for patients who received ≥1 plasma units and developed hypoxemia within 24 h.ResultsDuring the study period, 8944 patients were admitted to the ICU. Exactly 1171 quarantine fresh frozen plasma (qFFP) units were transfused in 376 patients, and respectively, 2008 SDP units to 396 patients after implementation. Ten TRALI cases occurred during the qFFP and nine cases occurred during the SDP period, in which plasma was transfused. The incidence was 0.85% (CI95%: 0.33%–1.4%) per unit qFFP and 0.45% (CI95%: 0.21%–0.79%, p = 0.221) per SDP unit. One instance of TRALI occurred after a single SDP unit. Mortality was 70% for patients developing TRALI in the ICU compared with 22% in patients receiving at least one plasma transfusion.ConclusionImplementation of SDP lowered the incidence of TRALI in which plasma products were implicated, though not significantly. Clinically diagnosed TRALI can still occur following SDP transfusion. Developing TRALI in the ICU was associated with high mortality rates, therefore, clinicians should remain vigilant.

TACO and TRALI: biology, risk factors, and prevention strategies.

Transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) are the leading causes of transfusion-related morbidity and mortality. These adverse events are characterized by acute pulmonary edema within 6 hours of a blood transfusion and have historically been difficult to study due to underrecognition and nonspecific diagnostic criteria. However, in the past decade, in vivo models and clinical studies utilizing active surveillance have advanced our understanding of their epidemiology and pathogenesis. With the adoption of mitigation strategies and patient blood management, the incidence of TRALI and TACO has decreased. Continued research to prevent and treat these severe cardiopulmonary events is focused on both the blood component and the transfusion recipient.

The Incidence of Transfusion-Related Acute Lung Injury at a Large, Urban Tertiary Medical Center: A Decade's Experience.

While transfusion-related acute lung injury (TRALI) remains the primary cause of transfusion-related fatalities (37%), recent reports estimate the incidence of TRALI at 0.008% per unit of plasma transfused and 0.004% per all products transfused. Because blood banks have moved toward male-predominant plasma, TRALI appears, anecdotally, to have been reduced to an extremely rare event. The purpose of this study was to estimate the current incidence of TRALI at a large, urban center known for its early and aggressive use of plasma in the setting of trauma, hemorrhagic shock, and massive transfusion. The Blood Bank Registry of our hospital was queried for all transfused patients admitted from September 2002 through March 2013. The blood bank collected and investigated all cases of clinical acute lung injury meeting the consensus definition for TRALI, as well as potential cases for which the donor product was recalled for having a high reactivity level of human leukocyte antigen antibodies (ie, the antibodies that could cause TRALI). Clinical reactions were reviewed in conjunction with independent serological testing and classified by transfusion medicine physicians as being "probable TRALI" or of "unrelated etiology." The total number of units transfused at our facility during this time period was also obtained, allowing the incidence of TRALI to be estimated. Cases were analyzed based on demographics, outcome, blood types, observed symptoms and their duration, and type of product transfused. Seven cases were identified at our center for the indicated time period, with only 3 of these occurring in trauma. A total of 714,757 units of blood products were transfused between September 2002 and March 2013. The incidence of TRALI was estimated to be 1 case per 100,000 units of product for the entire study period. A broad range of patients was affected. Consistent with previous descriptions, an acute duration of symptoms (average, 1.4 days) was observed and usually resolved with supportive care. Reactions were observed predominantly in plasma products, both type specific and nontype specific. This study demonstrates that while TRALI still occurs, clinically meaningful cases are rare. Moreover, TRALI rates remain low despite the increasingly aggressive use of plasma and platelets in the trauma setting.

Donor characteristics do not influence transfusion-related acute lung injury incidence in a secondary analysis of two case-control studies

ObjectiveTo investigate the relation between donor characteristics and TRALI incidence. BackgroundTransfusion-related acute lung injury (TRALI) is a potentially fatal complication of transfusion. In pre-clinical studies and several clinical studies, TRALI has been related to loss of product quality during red blood cell (RBC) storage, called the “storage lesion”. Donor characteristics, as for example age, genetics and life style choices influence this “storage lesion”. We hypothesized that donor sex, age and blood type is related to TRALI incidence. Methods/materialsWe performed a secondary analysis of two cohort studies, designed to identify TRALI risk factors by matching TRALI patients to transfused controls. We obtained donor sex, age and blood type from the Dutch Blood Bank Sanquin and investigated TRALI incidence in patients who were exposed to a certain donor characteristic. We used Kruskal-Wallis testing to compare the number of transfused products and Chi2 testing to compare proportions of TRALI patients and transfused control. ResultsAfter implementation of the male-donor only plasma strategy, patients received more transfusion products from male donors. However, we did not detect a relation between TRALI incidence and donor sex. Both TRALI patients and transfused controls received mainly products from donors over 41 years old, but donor age did not influence TRALI risk. Donor blood type, the transfusion of blood type-compatible and blood type-matched products also had no influence on TRALI incidence. ConclusionWe conclude that in two cohorts of TRALI patients, donor age, donor sex and donor blood type are unrelated to TRALI.

Kayo Sugiyama*, Hirotaka Watanuki, Masaho Okada, Yasuhiro Futamura, Atomu Tajima, Rokuki Kiyosawa, Katsuhiko Matsuyama

Transfusion-related acute lung injury (TRALI) is characterized by acute severe hypoxemia with bilateral noncardiogenic pulmonary edema after transfusion of a plasma-containing blood component. In patients undergoing cardiac surgery, the incidence of TRALI is high; however, the detailed clinical course is unknown. Here, we report a case of life-threatening TRALI following pulmonary thrombectomy, which was successfully treated with extracorporeal membranous oxygenation (ECMO).

Transfusion-related acute lung injury risk mitigation: an update.

Transfusion-related acute lung injury (TRALI) is a life-threatening complication of transfusion. Greater understanding of the pathophysiology of this syndrome has much improved during the last two decades. Plasma-containing components from female donors with leucocyte antibodies were responsible for the majority of TRALI fatalities before mitigation strategies were implemented. Over the past 15years, measures to mitigate risk for TRALI have been implemented worldwide and they continued to evolve with time. The AABB requires that all plasma containing components and whole blood for transfusion must be collected from men, women who have not been pregnant, or women who have tested negative for human leucocyte antigen antibodies. Although the incidence of TRALI has decreased following the institution of TRALI mitigation strategies, TRALI is still the most common cause of transfusion-associated death in the United States. In this review, we focus on TRALI risk mitigation strategies. We describe the measures taken by blood collection facilities to reduce the risk of TRALI in the United States, Canada and European countries. We also review the literature for the effectiveness of these measures.

Analysis of Transfusion-Related Acute Lung Injury and Possible Transfusion-Related Acute Lung Injury Reported to the French Hemovigilance Network From 2007 to 2013.

Using the French Hemovigilance Network database from 2007 to 2013, we provide information on demographics, incidence, and risk factors of reported transfusion-related acute lung injury (TRALI) and possible TRALI, analyze TRALI mitigation efforts for fresh frozen plasma and platelet concentrates, and consider the impact of platelet additive solutions on TRALI incidence. We applied the Toronto consensus conference definitions for TRALI and possible TRALI. Two TRALI subgroups were considered: "antibody positive" when a donor has human leukocyte antigen (class I or II) and/or human neutrophil antigen antibodies and the recipient has cognate antigen, and "antibody negative" when immunological investigation is negative or not done. The analysis targeted 378 cases, divided into antibody-positive TRALI (n=75), antibody-negative TRALI (n=100), and possible TRALI (n=203). TRALI patients were younger and received more blood components than the general population of transfused patients. Moreover, we identified the following clinical conditions where patients seemed to be at higher risk to develop TRALI: postpartum hemorrhage, acute myeloid leukemia, liver transplantation, allogeneic and autologous hematopoietic stem cells transplantation, polytrauma, and thrombotic microangiopathy. Policy measures intended to reduce antibody-positive TRALI were found effective for apheresis platelet concentrates and fresh frozen plasma but not for whole blood-derived platelet concentrates. The use of platelet additive solutions was associated with a significant reduction in the incidence of TRALI following transfusion of buffy coat-derived platelet concentrates but not following transfusion of apheresis platelets. Our data reinforce the concept that possible TRALI and TRALI, as defined in the Canadian consensus conference, share many characteristics. No specific policy measures are currently directed at mitigation of possible TRALI despite its impact on transfusion safety. Despite TRALI mitigation measures, the overall incidence of TRALI cases reported to the French Hemovigilance system was not significantly reduced. Therefore, additional research is needed to reduce, if not eradicate, all TRALI categories.

Possible TRALI is a real entity.

After the consensus definition of transfusion-related acute lung injury (TRALI), studies have shown that the incidence of TRALI is high in critically ill and injured patients. When another risk factor for lung injury is present in these patients, the term "possible TRALI" is used. In the past years, both animal and clinical studies have taught us that a predisposing inflammatory risk factor is frequently present in TRALI, if not mandatory. The decline in the incidence of TRALI after implementation of the use of male-only plasma as observed in general hospital patients is also seen in the critically ill and injured, suggesting that antibodies play a role in possible TRALI. Thereby, introduction of the term "possible TRALI" has helped us in estimating incidence rates as well as to understand risk factors for TRALI in patient populations with a high exposure to transfusion.

Transfusion-related acute lung injury (TRALI) after pediatric cardiac surgery: A case report

Transfusion-related acute lung injury (TRALI), acute respiratory distress with noncardiogenic pulmonary edema that occurs within six hours of transfusion, is the leading cause of transfusion-related deaths. However, there is no reliable literature regarding the incidence of TRALI in the pediatric population. We report a case study of a 3-year-old boy presenting with TRALI syndrome four hours after heart surgery for atrial septal defect (ASD) closure for which he received the transfusion of red blood cells and fresh frozen plasma. We report this case with the aim that doctors become aware of the signs of TRALI to enable early intervention and the development of preventive measures.

A Preliminary Analysis of the Incidence of Transfusion-Related Acute Lung Injury (TRALI) in a Sheep Model Following Transfusion with the Supernatant from Leukodepleted Red Cell Units

IntroductionDespite the introduction of risk reduction strategies, transfusion-related acute lung injury (TRALI) continues to be a significant cause of morbidity and mortality. TRALI development may be associated with the transfusion of anti-leucocyte antibodies or biological response modifiers (BRMs). Our group has previously developed a model in which the development of TRALI in lipopolysaccharide (LPS) treated sheep was precipitated by the transfusion of pooled supernatant from date-of-expiry (day (d) 42) packed red blood cell (PRBC) units. This work pre-dated the introduction of pre-storage leukodepletion of PRBCs in Australia, therefore we investigated whether TRALI would still develop in LPS-treated sheep transfused with supernatant from d42 leukodepleted PRBCs.MethodsOn either d2 (n=75 units) or d42 (n=113 units) of storage, leukodepleted PRBCs underwent dual centrifugation to obtain acellular supernatants. Two supernatant pools (d2 and d42) were then prepared by pooling and heat-treating (56°C for 30min) the supernatants. Levels of potential BRMs in the PRBC supernatant pools were characterised using cytometric bead array and ELISA. Instrumented sheep (n=14) were infused with LPS then transfused (10% v/v) with either d2 (n=7) or d42 (n=7) pooled PRBC supernatant. Two hours later sheep were euthanized and post-mortem lung samples were collected. Physiological data were recorded continuously and then averaged in 30 minute blocks for these preliminary analyses. Blood and broncoalveolar lavage (BAL) fluid samples were collected at specific intervals. Blood samples were used for arterial blood gas analyses, coagulation tests (ROTEM), platelet function tests (MultiPlate) and ELISAs. TRALI was defined by hypoxemia (PaO2/FiO2 < 300 on arterial blood gas) and histological evidence of pulmonary edema (by two blinded histopathological assessments of hematoxylin and eosin stained lung sections). Data were compared by group (sheep transfused with d2 PRBC supernatant vs. d42 PRBC supernatant) and by outcome (sheep who developed TRALI vs. those who did not) with either t-tests or 2-way ANOVAs as appropriate.Results and DiscussionStorage duration of leukodepleted PRBC was associated with increased levels of the potential BRMs 5-HETE, 12-HETE, 15-HETE and IL-8, but not soluble CD40 ligand. Only 3 sheep developed TRALI: one transfused with d2 leukodepleted PRBC supernatant and two transfused with d42 leukodepleted PRBC supernatant corresponding to an incidence of 14% and 29% respectively. This indicated a reduced incidence of TRALI in the sheep model compared to previous data using supernatant from d42 non-leukodepleted PRBC which resulted in an incidence of 75% (Tung et al. Vox Sanguinis. 2011). Preliminary analyses of the physiological data revealed a number of differences. Heart rate (P<0.001), blood pressure (P=0.003), pulmonary artery pressure (P<0.001), cardiac output (P<0.001) and PaO2/FiO2 (P<0.001) were different between sheep transfused with either d2 or d42 PRBC supernatant. Heart rate (P<0.001), pulmonary artery pressure (P<0.001), pulse oximeter oxygen saturation (P=0.003), cardiac output (P<0.001) and PaO2/FiO2 (P<0.001) were different between sheep that developed TRALI and sheep that did not. However, given the complexity of these data, further analyses using mixed effects modelling are required to better understand these differences. Sheep transfused with d42 PRBC supernatant had reduced IL-1β lung gene expression and reduced ADP-induced platelet aggregation (both total and area under curve) compared to sheep transfused with d2 PRBC supernatant (P=0.047, 0.012 and 0.028 respectively). In addition, sheep that developed TRALI had worse lung histology scores as well as reduced collagen-induced platelet aggregation (both total and area under curve) compared to sheep who did not develop TRALI (P=0.024, 0.049 and 0.018 respectively).ConclusionsComparison of these results to previously published data from the sheep model is suggestive that pre-storage leukodepletion of PRBCs is associated with a reduced incidence of TRALI. Unsurprisingly, the development of TRALI was associated with worsened respiratory function (oxygen saturation and PaO2/FiO2) and lung histology scores, while changes in hemodynamics and platelet function were also observed. DisclosuresFraser:Fisher and Paykel Healthcare: Consultancy, Other: Provision of equipment for research use, Research Funding; De Motu Cordis: Equity Ownership, Membership on an entity's Board of Directors or advisory committees.

A Clinical Trial to Detect Subclinical Transfusion-Induced Lung Injury During Surgery

Background:Transfusion-related acute lung injury incidence remains the leading cause of posttransfusion mortality. The etiology may be related to leukocyte antibodies or biologically active compounds in transfused plasma, injuring susceptible recipient’s lungs. The authors have hypothesized that tra

Research progress of transfusion related acute lung injury and its prevention and control strategies

Transfusion-related acute lung injury (TRALI) which occurs acute lung injury (ALI) within 6 hours after transfusion is one of the leading causes of death in patients with blood transfusion. Several hypothesises have been proposed to explain the underlying pathologic mechanisms of TRALI, such astwo-eventandthreshold modelhypothesis, etc.. Immune-mediated TRALI accounts for over 80% of reported cases of TRALI which was mediated by HLA (human leucocyte antigen) or human neutrophil antigens (HNA) antibodies in transfused blood products. Immune-mediated TRALI is commonly associated with donor plasma transfusion or other blood products from multiparous women, which has led many countries to reduce or exclude women from donating high-volume plasma products. This policy has resulted in a decrease in the incidence of TRALI. This article reviews the definition, pathogenesis, diagnosis, prevention and control strategies of TRALI. Key words: Transfusion related acute lung injury; Pathogenesis; Mitigation strategies

A Clinical Trial to Detect Subclinical Transfusion-induced Lung Injury during Surgery.

Transfusion-related acute lung injury incidence remains the leading cause of posttransfusion mortality. The etiology may be related to leukocyte antibodies or biologically active compounds in transfused plasma, injuring susceptible recipient's lungs. The authors have hypothesized that transfusion could have less severe effects that are not always appreciated clinically and have shown subtly decreased pulmonary oxygen gas transfer in healthy volunteers after transfusion of fresh and 21-day stored erythrocytes. In this study, the authors tested the same hypothesis in surgical patients. Ninety-one patients undergoing elective major spine surgery with anticipated need for erythrocyte transfusion were randomly allocated to receive their first transfusion of erythrocytes as cell salvage (CS), washed stored, or unwashed stored. Clinicians were not blinded to group assignment. Pulmonary gas transfer and mechanics were measured 5 min before and 30 min after erythrocyte transfusion. The primary outcome variable, gas transfer, as assessed by change of PaO2/FIO2, with erythrocyte transfusion was not significant in any group (mean ± SD; CS: 9 ± 59; washed: 10 ± 26; and unwashed: 15 ± 1) and did not differ among groups (P = 0.92). Pulmonary dead space (VD/VT) decreased with CS transfusion (-0.01 ± 0.04; P = 0.034) but did not change with other erythrocytes; the change from before to after erythrocyte transfusion did not differ among groups (-0.01 to +0.01; P = 0.28). The authors did not find impaired gas exchange as assessed by PaO2/FIO2 with transfused erythrocytes that did or did not contain nonautologous plasma. This clinical trial did not support the hypothesis of erythrocyte transfusion-induced gas exchange deficit that had been found in healthy volunteers.

The usefulness of a classification and regression tree algorithm for detecting perioperative transfusion-related pulmonary complications.

Transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) are leading causes of transfusion-related mortality. An electronic medical record-based screening classification and regression tree (CART) algorithm was previously developed for predicting transfusion-related pulmonary complications. In the Republic of Korea, TRALI is not sufficiently recognized and an accurate TRALI incidence has not been reported. Therefore, we carried out this study to assess the incidence of TRALI and to determine whether the CART algorithm can be applied to our hospital data. A retrospective analysis of all patients who received any type of transfusion during anesthesia was performed. After the patients were diagnosed by the relevant diagnostic criteria, they were reclassified by the CART algorithm. The validity of the algorithm was evaluated with sensitivity, specificity, likelihood ratios, and misclassification rate. Among 1948 patients who had received 11,269 units of transfusion, 26 TRALI and 20 TACO cases were identified. The incidence of TRALI among the transfused patients was 1.33% and per unit of transfused blood product was 0.23%. The sensitivity and specificity of the TRALI algorithm were estimated to be 73.1% (95% confidence interval [CI], 53.9%-86.3%) and 57.0% (95% CI, 52.5%-61.4%). For TACO, the sensitivity and specificity were 90.0% (95% CI, 69.9%-97.2%) and 56.0% (95% CI, 51.6%-60.4%), respectively. Low specificity of the CART algorithm adopted previously indicated its limited diagnostic value in the Republic of Korea. A new algorithm is needed to facilitate the detection of transfusion-related complications.

Antibody-mediated transfusion-related acute lung injury; from discovery to prevention.

Transfusion-related acute lung injury (TRALI), a syndrome of respiratory distress caused by blood transfusion, is the leading cause of transfusion-related mortality. The majority of TRALI cases have been related to passive infusion of human leucocyte antigen (HLA) and human neutrophil antigen (HNA) antibodies in donor blood. In vitro, exvivo and invivo animal models have provided insight in TRALI pathogenesis. The various classes of antibodies implicated in TRALI appear to have different pathophysiological mechanisms for the induction of TRALI involving endothelial cells, neutrophils, monocytes and, as very recently has been discovered, lymphocytes. The HLA and HNA-antibodies are found mainly in blood from multiparous women as they have become sensitized during pregnancy. The incidence of TRALI has decreased rapidly following the introduction of a male-only strategy for plasma donation. This review focuses on pre-clinical and clinical studies investigating the pathophysiology of antibody-mediated TRALI.

Male-predominant plasma transfusion strategy for preventing transfusion-related acute lung injury: a systematic review.

To assess 1) the effectiveness of male-predominant plasma transfusion strategy for preventing transfusion-related acute lung injury and related mortality; and 2) whether this effect varies across different patient subgroups. Systematic Review and meta-analysis: Data were identified by querying MEDLINE and EMBASE (including proceedings of major conferences on blood transfusions), searching the Internet for hemovigilance reports, reviewing reference lists of eligible articles and contacting experts in the field. Eligible were all studies reporting transfusion-related acute lung injury incidence, all-cause mortality (primary outcomes), hospital length of stay, time to extubation, PaO2/FIO2-ratio or blood pressure changes (secondary outcomes) in recipients of plasma transfusions containing relatively more plasma from individuals at low risk of carrying leukocyte-antibodies ("male plasma") than those receiving comparator plasma ("control plasma"). No limits were placed on study design, population or language. The only exclusion criteria were non-human subjects and lack of control group. Prespecified study quality indicators (including risk of bias assessment) and potential effect modifiers were tested using Cochran's Q Test. Final analyses using random-effects models and I2 to assess heterogeneity were performed in the subset of studies judged to provide the best evidence and separately for significantly different subgroups using STATA 12.1 (StataCorp, College Station, TX). As per primary studies. As per primary studies. As per primary studies (generally: exposure to plasma containing relatively more male plasma than comparator plasma). From a total of 850 retrieved records, we identified 45 eligible studies. For transfusion-related acute lung injury incidence, final analysis was restricted to 13 cohort studies and one randomized controlled trial in which transfusion-related acute lung injury cases only involved plasma transfusions. Risk of transfusion-related acute lung injury and mortality in plasma recipients exposed to men when compared with control plasma were 0.27 (95% CI, 0.20-0.38; p < 0.001; I = 0%; n = 14; 286 events) and 0.89 (95% CI, 0.80-1.00; p = 0.04; I = 79%; n = 7; 5, 710 events), respectively. No other significant interactions were found. Secondary outcomes showed similar results but were less reported and the studies were more heterogeneous. Sensitivity analyses did not alter the results. There was no evidence of publication bias. More than 800 million people in 17 countries are subject to male-predominant plasma transfusion policy and at least three more countries are planning or considering adoption of this strategy. On the basis of most observational data, judged to be of high quality, male-predominant plasma transfusion strategy reduces plasma-related transfusion-related acute lung injury incidence and possibly mortality. There was no evidence that the effect differs across patient subgroups, but power to detect such differences was low.